PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.12%
Both companies show declining cash positions (-5.12% vs GNPX's -8.07%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-5.12%
Cash + STI yoy 0.5-0.75x GNPX's -8.07%. Martin Whitman would worry about lagging short-term reserves. Confirm debt coverage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
820.83%
Higher Other Current Assets Growth compared to GNPX's zero value, indicating worse performance.
-4.22%
Below half of GNPX's -14.25%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-17.65%
Below half GNPX's 9.62%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both GNPX and the company show zero Long-Term Investments Growth.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of GNPX's 28119.85%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-47.54%
Below half of GNPX's 445.40%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-4.84%
0.5-0.75x GNPX's -7.48%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
46.70%
50-75% of GNPX's 64.41%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
-26.38%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
126.45%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
265.71%
Exceeding 1.5x GNPX's 7.40%. Michael Burry suspects ballooning short-term obligations vs. competitor.
63.25%
Above 1.5x GNPX's 36.44%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.00%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
63.16%
Above 1.5x GNPX's 36.44%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-3.23%
Below half GNPX's -7.85%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.40%
Similar yoy to GNPX's -8.61%. Walter Schloss sees parallel net worth trends.
-4.84%
0.5-0.75x GNPX's -7.48%. Martin Whitman sees underexpansion or possible missed opportunities.
-100.00%
Both GNPX and the company show zero Total Investments Growth.
-26.37%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
5.01%
50-75% of GNPX's 8.07%. Bruce Berkowitz notes comparatively lower net debt expansion.